MET International Seminar Series 2024
Organised by: Faculty of Medicine and Health Technology & Doctoral Programme in Medicine and Life Sciences
Lahtikari seminars 2024
13.3.2024
Matti Annala:
Landscape of AR locus alteration across 3555 plasma cfDNA samples from 2148 castration resistant prostate cancer patients
22.2.2024
Antti Kiviaho:
Spatial transcriptomics profiling implicates club-like cells as a driving force behind myeloid chemotaxis-induced castration resistance in prostate cancer
17.1.2024
Merja Helenius:
Tays Cancer Centre and audit in 2024
Lahtikari seminars 2023
14.12.2023
Reetta Nätkin:
Molecular profiling of the UV1-TERT vaccine trial.
8.11.2023
Taru Suoniemi:
Androgen deprivation therapy and mortality from coronary artery disease
12.10.2023
Anssi Auvinen:
Proscreen
24.8.2023
Dr Sven Löffeler, Vestfold hospital, Norway
SPCG-19 – A randomized, open-label, multicenter, parallel group treatment, phase 3, two-arm study to measure the effect on overall survival and quality of life of immediate curative therapy compared with standard conservative treatment in older male participants aged ≥ 75 years with non-metastatic, high-risk prostate cancer
14.6.2023
Alejandra Rodriquez Martinez and Elaheh Moradi:
Tumor diagnostics based on DNA methylation – the case of CNS tumors
10.5.2023
Anssi Auvinen:
ProScreen trial for prostate cancer screening
12.4.2023
Alfonso Urbanucci:
ATAD2: a promising drug target in prostate cancer treatment?
22.3.2023
Annastiina Hakulinen
MOVES clinical trial
15.2.2023
Steven Bova:
The nature of biomedical truth 2023
18.1.2023
Teemu Murtola:
PROLIB
Lahtikari seminars 2022
7.12.2022
Alfonso Urbanucci:
Screening and Molecular Characterization of Small-Molecule Inhibitors as Radiosensitizers for Prostate Cancer Treatment
2.11.2022
Christoffer Löf:
The role of aggressive prostate cancer risk gene ANO7 in prostate metabolism
12.10.22
Serafiina Jaatinen and Anja Hartewig:
Progression of IDH-mutant astrocytomas to grade 4 under treatment-related selection pressure
10.8.2022
Anssi Auvinen:
Update of the randomised trial of screening for clinically significant prostate cancer (ProScreen)
1.6.2022
Laura Lahti and Anna-Maija Talvitie:
Quality of life in men with prostate cancer
6.4.2022
Toni Seppälä:
Precision medicine approaches in gastrointestinal cancers
16.2.2022
Minna-Liisa Änkö:
Functional RNAomics
9.3.2022
Aino Siltari:
Role of lipid metabolism in prostate cancer cells
-hypoxia and immune response
Lahtikari seminars 2021
8.12.2021
Sara Hamis:
Bridging Spatial and Evolutionary Game Theory: Implications in
Mathematical Oncology
12.1.2021
Sari Tojkander:
Tampere Institute for Advanced Study Fellow
Biophysics in the Homeostasis of Epithelial Tissues